| Stereochemistry | ACHIRAL |
| Molecular Formula | C21H16F3N3O3.ClH |
| Molecular Weight | 451.826 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.FC(F)(F)OC1=CC=C(C=C1)C2=CC3=C(OCCN(CC4=NC=CC=N4)C3=O)C=C2
InChI
InChIKey=ZRYHNOXHGYUHFF-UHFFFAOYSA-N
InChI=1S/C21H16F3N3O3.ClH/c22-21(23,24)30-16-5-2-14(3-6-16)15-4-7-18-17(12-15)20(28)27(10-11-29-18)13-19-25-8-1-9-26-19;/h1-9,12H,10-11,13H2;1H
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
| 0.97 µM [IC50] |
PubMed
Patents
Sample Use Guides
Phase 3 clinical trial designed to determine the efficacy, safety, and tolerability of the late sodium current inhibitor eleclazine in shortening the corrected QT (QTcF) interval in subjects with type 3 Long QT Syndrome (LQT3). 41 subjects with genotype-confirmed LQT3 received a 48 mg oral loading dose of eleclazine followed by 12 weeks of treatment with 3 mg oral eleclazine once daily and then 12 weeks of treatment with 6 mg oral eleclazine once daily.
Route of Administration:
Oral
ACTIVE MOIETY
SUBSTANCE RECORD
